MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT02146170 | RECRUITING
2000 participants

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-28
Start Date:
2014-05-28
Completion:
2028-12-31
Conditions
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Extrapulmonary Small Cell Cancer
  • Pulmonary Neuroendocrine Tumors
  • Thymic Epithelial Tumors
No Results Yet
NCT02142803 | ACTIVE_NOT_RECRUITING | PHASE1
50 participants

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2014-05-20
Completion:
2020-12-31
Conditions
  • Adult Glioblastoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Ovarian Clear Cell Cystadenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Mucinous Cystadenocarcinoma
  • Ovarian Serous Cystadenocarcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Malignant Uterine Corpus Neoplasm
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Solid Neoplasm
  • Stage IIIA Fallopian Tube Cancer AJCC v7
  • Stage IIIA Ovarian Cancer AJCC v6 and v7
  • Stage IIIA Primary Peritoneal Cancer AJCC v7
  • Stage IIIB Fallopian Tube Cancer AJCC v7
  • Stage IIIB Ovarian Cancer AJCC v6 and v7
  • Stage IIIB Primary Peritoneal Cancer AJCC v7
  • Stage IIIC Fallopian Tube Cancer AJCC v7
  • Stage IIIC Ovarian Cancer AJCC v6 and v7
  • Stage IIIC Primary Peritoneal Cancer AJCC v7
  • Stage IV Fallopian Tube Cancer AJCC v6 and v7
  • Stage IV Ovarian Cancer AJCC v6 and v7
  • Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
  • BIOLOGICAL
  • OTHER
  • DRUG
Results Available
NCT02135042 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
924 participants

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2014-07-01
Completion:
2026-12-01
Conditions
  • EBV Infection
  • Stage II Nasopharyngeal Carcinoma AJCC v7
  • Stage III Nasopharyngeal Carcinoma AJCC v7
  • Stage IVA Nasopharyngeal Carcinoma AJCC v7
  • Stage IVB Nasopharyngeal Carcinoma AJCC v7
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
  • RADIATION
No Results Yet
NCT01886872 | ACTIVE_NOT_RECRUITING | PHASE3
547 participants

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2014-01-15
Completion:
2018-08-07
Conditions
  • Stage I Chronic Lymphocytic Leukemia
  • Stage II Chronic Lymphocytic Leukemia
  • Stage III Chronic Lymphocytic Leukemia
  • Stage IV Chronic Lymphocytic Leukemia
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • BIOLOGICAL
Results Available
NCT01856192 | ACTIVE_NOT_RECRUITING | PHASE2
349 participants

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2013-08-27
Completion:
2020-03-26
Conditions
  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
  • DRUG
  • OTHER
  • BIOLOGICAL
Results Available
NCT01841736 | ACTIVE_NOT_RECRUITING | PHASE2
171 participants

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2013-09-20
Completion:
2019-03-05
Conditions
  • Foregut Neuroendocrine Tumor
  • Hindgut Neuroendocrine Tumor
  • Metastatic Digestive System Neuroendocrine Tumor G1
  • Metastatic Neuroendocrine Tumor
  • Midgut Neuroendocrine Tumor G1
  • Neuroendocrine Tumor G2
  • Recurrent Digestive System Neuroendocrine Tumor G1
  • Regional Digestive System Neuroendocrine Tumor G1
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
Results Available
NCT01631617 | RECRUITING | PHASE2
130 participants

Effects of Treatments on Atopic Dermatitis

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2012-09-18
Completion:
2027-01-01
Conditions
  • Eczema
  • Dermatitis
  • Skin Diseases, Genetic
  • Dermatitis, Atopic
  • Skin Diseases
Interventions
  • DRUG
  • OTHER
No Results Yet
NCT01272037 | ACTIVE_NOT_RECRUITING | PHASE3
5018 participants

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2011-02-28
Completion:
2023-02-01
Conditions
  • Breast Ductal Carcinoma In Situ
  • Invasive Breast Carcinoma
  • Multicentric Breast Carcinoma
  • Multifocal Breast Carcinoma
  • Synchronous Bilateral Breast Carcinoma
Interventions
  • DRUG
  • OTHER
Results Available
NCT01224704 | COMPLETED | NA
75 participants

Water Deprivation Protocol

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2010-10-19
Completion:
2018-09-09
Conditions
  • Obesity
Interventions
  • OTHER
No Results Yet
NCT01081262 | ACTIVE_NOT_RECRUITING | PHASE3
50 participants

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2010-10-12
Completion:
2015-02-25
Conditions
  • Borderline Ovarian Mucinous Tumor
  • Ovarian Mucinous Cystadenocarcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Stage IA Fallopian Tube Cancer AJCC v6 and v7
  • Stage IA Ovarian Cancer AJCC v6 and v7
  • Stage IB Fallopian Tube Cancer AJCC v6 and v7
  • Stage IB Ovarian Cancer AJCC v6 and v7
  • Stage IC Fallopian Tube Cancer AJCC v6 and v7
  • Stage IC Ovarian Cancer AJCC v6 and v7
  • Stage IIA Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIA Ovarian Cancer AJCC V6 and v7
  • Stage IIB Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIB Ovarian Cancer AJCC v6 and v7
  • Stage IIC Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIC Ovarian Cancer AJCC v6 and v7
  • Stage IIIA Fallopian Tube Cancer AJCC v7
  • Stage IIIA Ovarian Cancer AJCC v6 and v7
  • Stage IIIB Fallopian Tube Cancer AJCC v7
  • Stage IIIB Ovarian Cancer AJCC v6 and v7
  • Stage IIIC Fallopian Tube Cancer AJCC v7
  • Stage IIIC Ovarian Cancer AJCC v6 and v7
  • Stage IV Fallopian Tube Cancer AJCC v6 and v7
  • Stage IV Ovarian Cancer AJCC v6 and v7
Interventions
  • BIOLOGICAL
  • DRUG
  • OTHER
Results Available
NCT00588770 | ACTIVE_NOT_RECRUITING | PHASE3
403 participants

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2008-08-08
Completion:
2018-06-05
Conditions
  • Neck Squamous Cell Carcinoma of Unknown Primary
  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Verrucous Carcinoma
  • Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
  • Recurrent Neck Squamous Cell Carcinoma of Unknown Primary
  • Recurrent Oral Cavity Verrucous Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Recurrent Salivary Gland Carcinoma
  • Recurrent Sinonasal Squamous Cell Carcinoma
  • Salivary Gland Squamous Cell Carcinoma
  • Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage IV Major Salivary Gland Cancer AJCC v7
  • Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
  • Stage IVA Laryngeal Verrucous Carcinoma AJCC v7
  • Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
  • Stage IVA Major Salivary Gland Cancer AJCC v7
  • Stage IVA Oral Cavity Cancer AJCC v6 and v7
  • Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
  • Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7
  • Stage IVB Laryngeal Verrucous Carcinoma AJCC v7
  • Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
  • Stage IVB Major Salivary Gland Cancer AJCC v7
  • Stage IVB Oral Cavity Cancer AJCC v6 and v7
  • Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7
  • Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7
  • Stage IVC Laryngeal Verrucous Carcinoma AJCC v7
  • Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
  • Stage IVC Major Salivary Gland Cancer AJCC v7
  • Stage IVC Oral Cavity Cancer AJCC v6 and v7
  • Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
  • Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7
  • Tongue Carcinoma
Interventions
  • BIOLOGICAL
  • DRUG
  • OTHER
Results Available
NCT00569127 | ACTIVE_NOT_RECRUITING | PHASE3
427 participants

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2007-12-01
Completion:
2015-01-01
Conditions
  • Colorectal Neuroendocrine Tumor G1
  • Gastric Neuroendocrine Tumor G1
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumor
  • Neuroendocrine Tumor G2
Interventions
  • BIOLOGICAL
  • OTHER
  • DRUG
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page